Vineet Laboratories Limited (VINEETLAB.BO)
BSE · INR · Basic Materials · Chemicals
₹37.03 (+1.45%) as of
Key statistics
- Market cap
- 711.21M
- P/E (TTM)
- 15.18
- EPS (TTM)
- 2.44
- Dividend yield
- 0.00%
- 52-week range
- 28.00 – 51.84
- Beta
- 0.21
- Revenue (TTM)
- 595.05M
- Profit margin
- 1.87%
- Volume
- 1.25k
About Vineet Laboratories Limited
Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and fine chemicals primarily in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl-beta-d-thiogalactopyranoside, n-butyl lithium, 4-nitrophenyl phosphate disodium salt, 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside, 5-acetyl thiophene-2-carboxilic acid, 4-chlorobutyryl chloride, n-butyl magnesium chloride, 3-furaldehyde, 3-bromofuran, n-butylnitrite, ethyldiazo acetate, phenylboronic acid, 6-aminouracil, and 1-methyl-imidazole-2-carboxaldehyde. The company was incorporated in 2016 and is based in Hyderabad, India.
- Sector
- Basic Materials
- Industry
- Chemicals
- Headquarters
- Hyderabad, India
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.